Novartis Ag
-
{
- All
- News
- Videos
-
High Court Restrains Generic Pharma Firms From Making, Selling Patent Drug Of Novartis
The Delhi High Court has restrained various generic pharmaceutical companies from manufacturing or selling Valsartan and Sacubitril tablets, a combination to treat cardiovascular diseases, as it may amount to infringement of patent of pharma major
-
US sues Novartis over kickbacks, second case this week
The US government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs.
-
Novartis on patent setback: Will continue to invest in India, but cautiously
Novartis India Limited, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the country's top court rejected its plea for patent protection of its drug Glivec.
-
Supreme Court's decision on Novartis AG to benefit poor patients, say pharma companies
Poor patients will have easier access to quality medicines with the Supreme Court rejecting Swiss firm Novartis' patent plea for its cancer drug Glivec, according to domestic manufacturers.
-
Supreme Court backs generics in Novartis drug patent ruling
India's Supreme Court rejected Monday a patent bid by Swiss drug giant Novartis in a landmark ruling that activists say will protect access to cheap generic drugs and save lives in developing nations.
-
Supreme Court rejects Novartis AG's plea for cancer drug patent: Read full verdict
The Supreme Court has dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales. Here is the copy of the full verdict:
-
Novartis AG's plea for Glivec patent dismissed by Supreme Court
The Supreme Court dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.
-
Supreme Court's verdict on Novartis' plea for patent of cancer drug expected today
The Supreme Court will pronounce today its verdict on Swiss pharma giant Novartis AG's plea for getting its blood cancer drug Glivec patented in India and restraining Indian companies from manufacturing generic drugs.
-
High Court Restrains Generic Pharma Firms From Making, Selling Patent Drug Of Novartis
The Delhi High Court has restrained various generic pharmaceutical companies from manufacturing or selling Valsartan and Sacubitril tablets, a combination to treat cardiovascular diseases, as it may amount to infringement of patent of pharma major
-
US sues Novartis over kickbacks, second case this week
The US government on Friday announced its second civil fraud lawsuit against Novartis AG in four days, accusing a unit of the Swiss drugmaker of paying multimillion-dollar kickbacks to doctors in exchange for prescribing its drugs.
-
Novartis on patent setback: Will continue to invest in India, but cautiously
Novartis India Limited, a unit of Swiss drugmaker Novartis AG, will continue to file for patents in India, its vice chairman said on Monday, after the country's top court rejected its plea for patent protection of its drug Glivec.
-
Supreme Court's decision on Novartis AG to benefit poor patients, say pharma companies
Poor patients will have easier access to quality medicines with the Supreme Court rejecting Swiss firm Novartis' patent plea for its cancer drug Glivec, according to domestic manufacturers.
-
Supreme Court backs generics in Novartis drug patent ruling
India's Supreme Court rejected Monday a patent bid by Swiss drug giant Novartis in a landmark ruling that activists say will protect access to cheap generic drugs and save lives in developing nations.
-
Supreme Court rejects Novartis AG's plea for cancer drug patent: Read full verdict
The Supreme Court has dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a serious blow to Western pharmaceutical firms who are increasingly focusing on India to drive sales. Here is the copy of the full verdict:
-
Novartis AG's plea for Glivec patent dismissed by Supreme Court
The Supreme Court dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics.
-
Supreme Court's verdict on Novartis' plea for patent of cancer drug expected today
The Supreme Court will pronounce today its verdict on Swiss pharma giant Novartis AG's plea for getting its blood cancer drug Glivec patented in India and restraining Indian companies from manufacturing generic drugs.
